Biosimilars Access and Affordability Act
Latest Action
Read twice and referred to the Committee on Finance.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Biosimilars Access and Affordability Act (S. 5459) was a Senate bill introduced in the 118th Congress aimed at addressing issues related to the availability and cost of biosimilar drugs. Although the official summary and full text are not available, the bill's title and policy area indicate a focus on improving access to biosimilar medications, which are alternatives to biologic drugs and typically less expensive. The bill was read twice and referred to the Senate Committee on Finance but ultimately failed or expired without further action.
S. 5459 sought to improve access and affordability of biosimilar drugs but did not advance beyond committee referral and expired in the 118th Congress.
- The bill was introduced in the Senate during the 118th Congress and referred to the Committee on Finance.
- It focused on the health policy area, specifically targeting biosimilar drugs to enhance access and affordability.
- The bill did not progress past committee referral and is currently classified as failed or expired.
['Patients seeking more affordable biosimilar medications', 'Healthcare providers prescribing biosimilars', 'Pharmaceutical companies involved in biosimilar development and distribution', 'Health insurance plans aiming to reduce drug costs']
['Lack of detailed bill text limits understanding of specific implementation mechanisms or funding sources', 'Potential challenges in regulatory oversight or enforcement related to biosimilar approval and market competition', 'Unclear cost implications for federal healthcare programs or private insurers', 'No information on how the bill addresses patent or exclusivity issues that affect biosimilar market entry']
The bill was introduced in the Senate and referred to the Committee on Finance, a key committee for health-related legislation involving Medicare and Medicaid drug coverage. The failure to advance suggests either competing legislative priorities or unresolved policy questions within the committee or broader Senate. The bill fits within ongoing congressional efforts to manage drug costs and increase access to biologic alternatives.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential reduction in healthcare spending if biosimilar access and affordability improve', 'Possible increased competition in the pharmaceutical market for biologic drugs', 'Changes in prescribing patterns by healthcare providers favoring biosimilars', 'Impact on innovation incentives for biologic drug manufacturers depending on policy details']
The lack of an official summary and full bill text limits transparency and public understanding of the bill's provisions and potential impacts. Tracking the bill's referral to the Committee on Finance without further action highlights the importance of committee processes in legislative progress. Future transparency would benefit from timely publication of bill texts and summaries to enable comprehensive analysis.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.